Literature DB >> 28809609

The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.

Tian Zhang1, Andrew J Armstrong1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28809609     DOI： 10.1200/JCO.2017.74.7931

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Cabazitaxel suppresses the proliferation and promotes the apoptosis and radiosensitivity of castration-resistant prostate cancer cells by inhibiting PI3K/AKT pathway.

Authors:  Zheng Xu; Luwei Xu; Yuzheng Ge; Hongbin Sun; Jiageng Zhu; Quanliang Dou; Ruipeng Jia
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

2.  Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?

Authors:  Loma Al-Mansouri; Malmaruha Arasaratnam; Howard Gurney
Journal:  Eur J Hosp Pharm       Date:  2019-06-14

3.  Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study.

Authors:  Kristine Kreis; Dirk Horenkamp-Sonntag; Udo Schneider; Jan Zeidler; Gerd Glaeske; Lothar Weissbach
Journal:  Pharmacoecon Open       Date:  2021-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.